Discovery of new CCK2 receptor antagonists. A review of pharmacological studies. Part I: Development of potential therapeutic tools for gastrin- related gastrointestinal diseases

Methods and Findings in Experimental and Clinical Pharmacology

Volumn 21, Issue 5, 1999, Pages 375-383

  Revel, Laura ^a   Makovec, Francesco ^b  

^a PROUS SCIENCE   (Spain)

^b Rotta Research Laboratorium   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

1 (2,3 DIHYDRO 1 METHYL 2 OXO 5 PHENYL 1H 1,4 BENZODIAZEPIN 3 YL) 3 (3 METHYLPHENYL)UREA; 1 [5 (3 AZABICYCLO[3.2.2]NON 3 YL) 2,3 DIHYDRO 1 METHYL 2 OXO 1H 1,4 BENZODIAZEPIN 3 YL] 3 (3 METHYLPHENYL)UREA; CHOLECYSTOKININ OCTAPEPTIDE; CHOLECYSTOKININ RECEPTOR BLOCKING AGENT; CHOLECYSTOKININ RECEPTOR STIMULATING AGENT; GASTRIN; GASTRIN 17; L 368935; L 369466; L 708474; L 736309; L 736380; L 737481; L 738425; L 747238; L 751892; LY 191009; LY 242040; LY 262684; LY 262691; N (4 BROMOPHENYL) 3 OXO 4,5 DIPHENYL 1 PYRAZOLIDINECARBOXAMIDE; NEW DRUG; RB 210; RB 211; RP 69758; RP 71267; RP 71483; RP 72540; SPIROGLUMIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; CHOLECYSTOKININ RECEPTOR; GASTROINTESTINAL AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; DRUG RECEPTOR BINDING; ENTEROCHROMAFFIN CELL; GASTROINTESTINAL DISEASE; HIPPOCAMPUS; HUMAN; HYPERGASTRINEMIA; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MOUSE; NERVE CELL; NONHUMAN; ORAL DRUG ADMINISTRATION; REVIEW; STOMACH PARIETAL CELL; SUBCUTANEOUS DRUG ADMINISTRATION; ANIMAL; DRUG ANTAGONISM; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANIMALS; GASTRINS; GASTROINTESTINAL AGENTS; GASTROINTESTINAL DISEASES; HUMANS; RECEPTORS, CHOLECYSTOKININ;

EID: 0032588975     PISSN: 03790355     EISSN: None     Source Type: Journal    
DOI: 10.1358/mf.1999.21.5.541916     Document Type: Review

References (115)

1. Mutt, V., Jorpes, J. Structure of porcine cholecystokinin-pancreozymin. Eur J Biochem 1968, 6: 156-62.
2. Dockray, G.J.R. Immunochemical evidence of cholecystokinin-like peptides in brain. Nature 1976, 264: 568-70.
3. Frey, P. Cholecystokinin octapeptide (CCK 26-33), nonsulfated octapeptide and tetrapeptide (CCK 30-33) in rat brain: analysis by high pressure liquid chromatography (HPLC) and radioimmunoassay (RIA). Neurochem Int 1983, 5: 811-5.
4. Eberlein, G.A., Eysselein, V.E., Goebell, H. Cholecystokinin-58 is the major molecular form in man, dog and cat but not in pig, beef and rat intestine. Peptides 1988, 9: 993-8.
5. Rehfeld, J.H., Nielsen, F.C. Molecular forms and regional distribution of cholecystokinin in the central nervous system. In: Cholecystokinin and Anxiety. Bradwein, J., Vasar, E. (Eds.). RG Landes Companies 1995, 33-56.
6. Dockray, G.J., Gregory, R.A., Hutchinson, J.B. et al. Isolation, structure and biological activity of two cholecystokinin octapeptides from sheep brain. Nature 1978: 359-61.
7. Muller, J.E., Straus, E., Yalow, R.S. Immunohistochemical localization in rabbit brain of a peptide resembling the COOH-terminal octapeptide of cholecystokinin. Proc Natl Acad Sci USA 1977, 74: 3035-7.
8. Walsh, J.H. Gastrin. In: Gut Peptides. Walsh, J.H., Dockray, G.J. (Eds.). Raven Press: New York 1994, 75-121.
9. Rehfeld, J.F., Van Solinge, W. W. The tumor biology of gastrin and cholecystokinin. Adv Cancer Res 1994, 63: 295-347.
10. Watson, S., Abbott, A. TIPS receptors nomenclature supplement. Trends Pharmacol Sci 1992, Suppl 11.
11. Kopin, A.S., Lee, Y.M., McBride, L.J. et al. Expression cloning and characterization of the canine parietal cell gastrin receptor. Proc Natl Acad Sci USA 1992, 89, 3605-9.
12. Wank, S.A., Pisegna, J.R., Weerth, A.D. Brain and gastrointestinal cholecystokinin receptor family: structure and functional expression. Proc Natl Acad Sci USA 1992, 89: 8691-5.
13. Innis, R.B., Snyder, S.H. Distinct cholecystokinin receptors in brain and pancreas. Proc Natl Acad Sci USA 1980, 77: 6917-28.
14. Beinfeld, M.C. Cholecystokinin in the central nervous system: a minireview. Neuropeptides 1983, 3: 411-427.
15. Roques, B.P., Noble, F. Cholecystokinin receptors. The IUPHAR Compendium of Receptor Characterization and Classification 1998, 127-133.
16. Hill, D.R., Shaw, T.M., Graham, W., Woodruff, G.N. Autoradiographical detection of cholecystokinin-A receptors in primate brain using 1251-Bolton Hunter CCK-8 and 3H-MK-329. J Neurosci 1990, 10: 1070-81.
17. Hill, D.R., Shaw, T.M., Dourish, C.T., Woodruff, G.N. CCK-A receptors in the rat interpeduncular nucleus: evidence for a presynaptic location. Brain Res 1990, 454: 101-5.
18. Moran, T.H., Robinson, P.H., Goldrich, M.S., McHugh, P.R. Two brain cholecystokinin receptors: implications for behavioral actions. Brain Res 1986, 362: 175-9.
19. Singh, P., Townsend, C. M., Thompson, J.C., Naraayan, S., Guo, Y.S. Hormones in colon cancer: past and prospective studies. Cancer J 1990, 3: 28-33.
20. Watson, S., Steele, R. Gastrin receptors on gastrointestinal tumor cells. In: Gastrin receptors in gastrointestinal tumors. CRC 1993, 20-35.
21. Song, I., Brown, R.B., Wiltshire, R.N., Gantz, I., Trent, J.M., Yamada, T. The human gastrin/cholecystokinin type B receptor gene: alternative splice donor site in exon 4 generates two variant mRNAs. Proc Natl Acad Sci USA 1993, 90: 9085-9.
22. Rovati, A.L., Casula, P.L., Dare, G. Antisecretory action of some new compounds free of anti-cholinergic actions. Minerva Med 1967, 58: 3651-3.
23. Rassmussen, K. Therapeutic potential of cholecystokinin-B antagonists. Exp Opin Invest Drugs 1995, 4: 313-22.
24. Revel, L., Makovec, F. Update on nonpeptide CCK-B receptor antagonists. Drugs Fut 1998, 23: 751-66.
25. Watson, S.A. Gastrin antagonists and gastrointestinal tumors. Exp Opin Invest Drugs 1995, 4: 1253-66.
26. 3H]-cholecystokinin 8 as radioligand. J Neurosci 1984, 4: 1021-33.
27. Clark, C.R., Daum, P., Hughes, J. A study of the cerebral cortex cholecystokinin receptor using two radiolabelled probes: evidence for a common CCK 8 and CCK 4 cholecystokinin binding site. J Neurochem 1986, 46: 1094-101.
28. 26-33): evidence for CCK-B receptor heterogeneity. J Pharmacol Exp Ther 1990, 255: 1278-86.
29. 3H]-SNF8702. Mol Pharmacol 1992, 41: 1089-95.
30. 3H]L-365260: a new potent and selective brain cholecystokinin (CCK-B) and gastrin receptor antagonist radioligand. Mol Pharmacol 1989, 35: 803-8.
31. 3H]-PD-140376: a novel and highly selective antagonist radioligand for the cholecystokininB/gastrin receptor in guinea pig cerebral cortex and gastric mucosa. Mol Pharmacol 1993, 43: 595-602.
32. 125I-CCK-8 probe. J Recept Res 1983, 3: 647-65.
33. Lee, Y.M., Beinborn, M., McBride, E.W., Lu, M., Kolakowski, L.F., Kopin, A.F. The human brain cholecystokinin-B/gastrin receptor. J Biol Chem 1993, 268: 8164-9.
34. Dunlop, J., Brammer, N., Ennis, C. Pharmacological characterization of a Chinese hamster ovary cell line transfected with the human CCK-B receptor gene. Neuropeptides 1996, 30: 359-63.
35. Sankaran, H., Goldfine, I.D., Deveney, C.W., Wong, K.Y., Williams, J.A. Binding of cholecystokinin to high affinity receptors on isolated rat pancreatic acini. J Biol Chem 1980, 255: 1849-53.
36. 2+ in the peptic and parietal cells of the rabbit gland. J Biol Chem 1986, 261: 2260-6.
37. 2+]i by secretagogue stimulation of canine gastric parietal cells. Am J Physiol 1992, 262: G420-G426.
38. Kuwahara, T., Nagase, H., Takamiya, M., Yoshizaki, H., Nakano, A., Arisawa, M. Activation of CCK-B receptors elevates cytosolic Ca2+ levels in a pituitary cell line. Peptides 1993, 14: 801-5.
39. Smith, A.J., Patel, S., Freedman, S.B. Characterization of CCKB receptors on GH3 pituitary cells: receptor activation is linked to Ca2+ mobilization. Eur J Pharmacol 1994, 267: 215-23.
40. Koizumi, T., Saita, Y., Miyake, A., Nishida, A., Yazawa, H., Honda, K. Antagonistic effect of YM022, an antiulcer agent in rats, on human cholecystokinin (CCK)B/gastrin receptor. Jpn J Pharmacol 1996, 71: 307-13.
41. Bohme, G.A., Stutzman, J.M., Blanchard, J.C. Excitatory effects of cholecystokinin in rat hippocampus: pharmacological response compatible with central or B-type CCK receptors. Brain Res 1988, 451: 309-18.
42. Daugè, G.A., Bohme, J.N. Crawley, C. et al. Investigation of behavioral and electrophysiological responses induced by selective stimulation of CCKB receptors by using a new highly potent CCK analog, BC 264. Synapse 1990, 6: 73-80.
43. Gosh, M.N., Shild, H.O. Continuous recording of acid gastric secretion in the rat. Br J Pharmacol Chemother 1958, 13: 54-61.
44. Lai, K.S. Studies on gastrin. Gut 1964, 5: 327-32.
45. Pendley, C.E., Fitzpatrick, L.R., Ewing, R.W., Molino, B.F., Martin, G.E. The gastrin/cholecystokinin-B receptor antagonist L-365,260 reduces basal acid secretion and prevents gastrointestinal damage induced by aspirin, ethanol and cysteamine in the rat. J Pharmacol Exp Ther 1993, 1348-54.
46. Nishida, A., Yuki, H., Tsutsumi, R. et al. L-365260, a potent gastrin/CCK-B receptor antagonist, suppress gastric acid secretion induced by histamine and betanechol as well as pentagastrin in rat. Jpn J Pharmacol 1992, 58: 137-45.
47. Lee, Y.H, Thompson, J.H. Response of rats with chronic gastric fistulas to subcutaneous injection of histamine, ICI-50123 and insulin. Am J Dig Dis 1969, 14: 14-29.
48. Kovac, T.O.G., Walsh, J.H., Maxwell, V. et al. Gastrin is a major mediator of the gastric phase of acid secretion in dogs: proof by monoclonal antibody neutralization. Gastroenterology 1989, 97: 1406-13.
49. Heidenhain, R. Uber die absonderung der fundusdrusen des magens. Pfluegers Arch 1879, 19: 148-66.
50. Davenport, H.D. Gastric mucosal injury by fatty and acetylsalicylic acids. Gastroenterology 1964, 46: 245-53.
51. Lippman, W. Inhibition of indomethacin-induced gastric ulceration in the rat by perorally administered synthetic and natural prostaglandin analogues. Prostaglandins 1974, 7: 1-9.
52. Lichetnberger, L.M., Szabo, S., Trier, J.S. Duodenal ulcerogens cysteamine, and propionitrile, stimulate serum gastrin levels in the rat. Gastroenterology 1977, 73: 1305-8.
53. Okabe, S., Ishihara, Y., Inoo, H., Tanaka, H. Mepirizole-induced duodenal ulcers in rat and their pathogenesis. Dig Dis Sci 1982, 27: 242-9.
54. Håkanson, R., Blom, H., Carlsson, E., Larsson, B., Ryberg, B., Sundler, F. Hypergastrinemia produces trophic effect in stomach but not in pancreas and intestine. Regul Pept 1986, 13: 225-33.
55. Håkanson, R., Tielemans, Y., Chen, D. et al. The biology and pathobiology of the ECL cells. Yale J Biol Med 1992, 65: 761-74.
56. Roche, S., Gusdinar, T., Bali, J.P., Magous, R. Gastrin and cholecystokinin receptors on histamine- and somatostatin-containing cells from rabbit fundic mucosa. Characterization by means of selective antagonists L-364,718 and L-365,260. Biochem Pharmacol 1991, 42: 771-6.
57. Sandvik, A.K., Waldum, H.L. Cholecystokinin-B (gastrin) receptor regulates gastrin histamine release and acid secretion. Am J Physiol 1991, 260: G925-G928.
58. Ekman, L., Hansson, E., Havu, N., Carlsson, E., Lundbeg, G. Toxicological studies on omeprazole. Scand J Gastroenterol 1985, 20:, Suppl. 108: 53-69.
59. Poynter, C., Pick, R.C., Harcourt, R.A. et al. Association of long-lasting unsurmountable histamine H2 blockade and gastric carcinoid tumors in the rat. Gut 1985, 26: 1284-95.
60. Prinz, C., Kaimura, M., Scott, D.R., Mercier, M., Helander, H.F., Sachs, G. Histamine secretion from rat enterochromaffin-like cells. Gastroenterology 1993, 105: 449-61.
61. Ding, X-Q., Håkanson, R. Evaluation of the specificity and potency of a series of cholecystokinin-B/gastrin receptor antagonists in vivo. Pharmacol Toxicol 1996, 79: 124-30.
62. Nishida, A., Kobayashi, A., Azukawa, S. et al. Gastrin receptor antagonist YM-022 prevents hypersecretion after long-term acid suppression. Am J Physiol 1995, 269: G699-G705.
63. Eissle, R., Parberg, H., Koop, H. et al. Effect of gastric receptor blockade on endocrine cells in rats during achlorhydria. Gastroenterology 1992, 103: 1596-601.
64. Brenna, E., Waldum, H.L. Studies of isolated parietal and enterochromaffin-like cells from the rat. Scan J Gastroenterol 1991, 26: 1295-306.
65. Watson, S., Durrant, L., Elston, P. Morris, D. Inhibitory effects of the gastrin receptor antagonist (L-365,260) on gastrointestinal tumor cell. Cancer 1991, 68: 1255-60.
66. Artru, P., Attoub, S., Levasseur, S., Lewin, M.J., Bado, A. Gastrin-17 and G17-gly induce proliferation of LoVo cells through the CCK B/gastrin receptor. Gastroenterol Clin Biol 1998, 22: 607-12.
67. Romani, R., Howes, L.G., Morris, D.L. Gastrin receptor antagonist CI-988 inhibits growth of human colon cancer in vivo and in vitro. Aust N Z J Surg 1996, 66: 235-7.
68. Piontek, M.K., Hengels, K.J. Differential mode of action of high- and low-affinity CCK/gastrin receptor antagonists in growth inhibition of gastrin-responsive human gastric adenocarcinoma cells in vitro. Anticancer Res 1993, 13: 715-20.
69. Watson, S.A., Crosbee, D.M., Morris, D.L. et al. Therapeutic effect of the gastrin receptor antagonist, CR 2093 on gastrointestinal tumor cell growth. Br J Cancer 1992, 65: 879-83.
70. Fukamizu, Y., Nakaijma, T., Kimura, K. et al. Biochemical and pharmacological profiles of loxiglumide, a novel cholecystokinin-A receptor antagonist. Arzneim-Forsch Drug Res 1998, 48: 58-64.
71. Pendley, C.E., Fitzpatrick, L.R., Capolino, A.L. et al. RP 73870, a gastrin/cholecystokinin-B receptor antagonist with potent antiulcer activity in the rat. J Pharmacol Exp Ther 1995, 273: 1015-22.
72. Lowe, J.A., Hageman, D.L., Drodza, S.E. et al. 5-Phenyl-3-ureidobenzazepin-2-ones as cholecystokinin-B receptor antagonists. J Med Chem 1994, 37: 3789-811.
73. Makovec, F., Peris, W., Revel, L., Giovanetti, R., Mennuni, L. Rovati, L.C. Structure-antigastrin activity relationships of new (R)-4-benzamido-5-oxopentanoic acid derivatives. J Med Chem 1992, 35: 28-38.
74. Rovati, L.C., D'Amato, M., Peris, W., Revel, L., Makovec, F. Selectivity and potency of new basic CCK-B antagonists. Ann NY Acad Sci 1994, 713: 395-7.
75. 2+ evaluation in rabbit parietal cells: a novel method to screen gastrin receptor antagonists. Eur J Pharm 1996, 306: 325-33.
76. Revel, L., Mennuni, L., Garofalo, P., Makovec, F. CR 2945: a novel CCKB receptor antagonist with anxiolytic-like activity. Behav Pharmacol 1988, 9: 183-194.
77. Takeda, Y., Kawagoe, K., Yokomizo, A. et al. Synthesis of phenoxyacetic acid derivatives as highly potent antagonists of gastrin/cholecystokinin-B receptors. Chem Pharm Bull 1998, 46: 434-44.
78. Tabuchi, S. et al. Dual CCK-A and CCK-B receptor antagonists (I). C9-methyl-1,4-benzodiazepines. Bioorg Med Chem Lett 1997, 7: 169-74.
79. nd Conf Drug Discov (Nov 19-21, Tsukuba) 1997, Abst 1-P-26.
80. Trist, G. et al. Anxiolytic activity of GV 150013, a new potent and selective cholecystokinin-B (CCK-B) antagonist. Eur Neuropsychopharmacol 1996, 6 (Suppl 3): Abst P-10-24.
81. th Symp Med Chem (Sept 8-12, Maastricht) 1996: Abst P-6.57.
82. Harper, E.A., Roberts, S.P., Shankley, N.P., Black, J.W. Analysis of variation in L-365,260 competition curves in radioligand binding assays. Br J Pharmacol 1996, 118: 1717-26.
83. Bock, M.G., Di Pardo, R.M., Mellin, E.C. et al. Second-generation benzydiazepine CCK-B antagonists. Development of subnanomolar analogs with selectivity and water solubility. J Med Chem 1994, 37: 722-4.
84. Chambers, M.S. et al. Potent, selective, water-soluble benzodiazepine-based CCKB receptor antagonists that contain lipophilic carboxylate surrogates. Bioorg Med Chem Lett 1995, 5: 2303-8.
85. Castro, J.L., Ball, R.G., Broughton, H.B., et al. Controlled modification of acidity in cholecystokinin B receptor antagonists: N-(1,4-Benzodiazepin-3-yl)-N′-[3-(tetrazol-5-ylamino) phenyl]ureas. J Med Chem 1996, 39: 842-849.
86. B/gastrin receptor antagonists containing a cationic solubilizing group. J Med Chem 1994, 37: 719-21.
87. Castro, J.L., Broughton, H.B., Russel, M.G.N. et al. 5-(piperidin-2-yl)- and 5-(homopiperidin-2-yl)-1,4-benzodiazepines: high-affinity, basic ligands for the cholecystokinin-B receptor. J Med Chem 1997, 40: 2491-501.
88. Howbert, J.J., Lobb, K.L., Brown, F.R. et al. A novel series of non-peptide CCK and gastrin antagonists: medicinal chemistry and electrophysiological demonstration of antagonism. In: Multiple Cholecystokinin Receptors - Progress Towards CNS Therapeutic Targets. Dourish C.T., S.J. Cooper (Eds.). Oxford University Press: London 1992, 28-37.
89. B/gastrin receptor antagonists. Eur J Pharmacol 1994, 262: 233-45.
90. 3H]-PD-140376. Regul Pept 1996, 65: 37-43.
91. Singh, L., Field, M.J., Hill, D.R., et al. Peptoid CCK receptor antagonists: pharmacological evaluation of CCKA, CCKB and mixed CCKA/B receptor antagonists. Eur J Pharmacol 1995, 286: 185-91.
92. Blommaert, A.G., Weng, J.H., Dorville, A. et al. Cholecystokinin peptidomimetics as selective CCK-B antagonists: design, synthesis and in vitro and in vivo biochemical properties. J Med Chem 1993, 36: 2868-77.
93. Blommaert, A.G., Dhotel, H., Ducos, B. et al. Structure-based design of new constrained cyclic agonists of the cholecystokinin CCK-B receptor. J Med Chem 1997, 40: 647-658.
94. Bohme, G.A., Bertrand, P., Guyon, C. et al. The ureidoacetamides, a novel family of non-peptide CCK-B/gastrin antagonists. Ann NY Acad Sci 1994, 713: 118-20.
95. Bertrand, P. et al. RPR 101367, a new potent and selective non-peptide CCK-B receptor antagonist. Br J Pharmacol 1995, 116(Suppl): Abst 241P.
96. Hagishita, S., Murakami, Y., Seno, K. et al. Synthesis and pharmacological properties of ureidomethylcarbamoylphenylketone derivatives. A new potent and subtype-selective nonpeptide CCK-B/gastrin receptor antagonists, S-0509. Bioorg Med Chem 1997, 5: 1695-714.
97. Semple, G., Ryder, H., Rooker, D.P. et al. (3R)-N-(tert-butylcarbonylmethyl)-2,3-dihydro-2-oxo-5-(2-pyridyl)-1H-1,4- benzodiazepin-3-yl)-N′-(3-(methylamino)phenyl)urea (YF476): a potent and orally active gastrin/CCK-B antagonist. J Med Chem 1997, 40: 331-41.
98. Takinami, Y., Yuki, H., Nishida, A. et al. YF476 is a new potent and selective gastrin/cholecystokinin-B receptor antagonist in vitro and in vivo. Aliment Pharmacol Ther 1997, 11: 113-20.
99. th ACS Natl Meet (Aug 20-24) 1995: Abst MEDI 166.
100. Satoh, M., Okamoto, Y., Koshio, H. et al. Biological activity of analogues of YM022. Novel (3-amino substituted phenyl) urea derivatives of 1,4-benzodiazepin-2-one as gastrin/cholecystokinin-B receptor antagonists. Chem Pharm Bull 1996, 44: 1412-4.
101. Satoh, M., Kondoh, Y., Okamoto, Y. et al. New 1,4-benzodiazepin-2-one derivatives as gastrin/cholecystokinin-B antagonists. Chem Pharm Bull 1995, 43: 2159-67.
102. Makovec, F., Peris, W., Frigerio, S. et al. Structure-antigastrin activity relationships of new spiroglumide amido acid derivatives. J Med Chem 1996, 39: 135-42.
103. Boden, P.R, Pinnock, R.D., Pritchard, M.C., Woodruff, G.N. Evaluation of a series of novel CCKB antagonists using a functional assay in the rat central nervous system. Br J Pharmacol 1994, 112: 666-70.
104. Revel, L., Ferrari, F., Makovec, F., Rovati, L.C., Impicciatore, M. Characterization of antigastrin activity in vivo of CR2194, a new R-4-benzamido-5-oxo-pentanoic acid derivative. Eur J Pharmacol 1992, 216: 217-24.
105. B receptor antagonist. Gut 1997, 41 (Suppl 3): A82.
106. Lotti, V.J., Chang, R.S.L. A new potent and selective non-peptide gastrin antagonist and brain cholecystokinin receptor (CCK-B) ligand: L-365,260. Eur J Pharmacol 1989, 162: 273-80.
107. Patel, S., Smith, A.J., Chapman, K.L. et al. Biological properties of the benzodiazepine amidine derivative L-740,093, a cholecystokinin-B/gastrin receptor antagonist with high affinity in vitro and high potency in vivo. Mol Pharmacol 1994, 46: 943-8.
108. Nishida, A., Miyata, K., Tsutsumi, R. et al. Pharmacological profile of (R)-1-[2,3-dihydro-1-(2′-methyl-phenacyl)-2-oxo-5-phenyl-1H-1,4- benzodiazepin-3-yl]-3-(3-methylphenyl)urea (YM022), a new potent and selective gastrin/cholecystokinin-B receptor antagonist, in vitro and in vivo. J Pharmacol Exp Ther 1994, 269: 725-31.
109. B/gastrin antagonists on stimulated gastric acid secretion in the anaesthetized rat. Br J Pharmacol 1991, 104:973-7.
110. Horwell, D.C., Hughes, J., Hunter, J.C. et al. Rationally designed "dipeptoid" analogues of CCK. alpha-methyltryptophan derivatives as highly selective and orally active gastrin and CCK-B antagonists with potent anxiolvtic properties. J Med Chem 1991, 34: 404-14.
111. Trivedi, B.K., Padia, J.K., Holmes, A. et al. Second generation "peptoid" CCK-B receptor antagonists: identification and development of N-(adamantyloxycarbonyl)-alpha-methyl-(R)-tryptophan derivative (CI-1015) with an improved pharmacokinetic profile. J Med Chem 1998, 41: 38-45.
112. Takemoto, Y. et al. Antisecretory effects of YF476, gastrin/CCK_B receptor antagonist, in beagle dogs with gastric fistula. Jpn J Pharmacol 1997, 73 (Suppl 1): Abst P-405.
113. Yuki, H., Nishida, A., Miyake, A. et al. YM022, a potent and selective gastrin/CCK-B receptor antagonist, inhibits peptone meal-induced gastric acid secretion in Heidenhain pouch dogs. Dig Dis Sci 1997, 42: 707-4.
114. Takemoto, T., Yuki, H., Nishida, A. Effects of YF476, a potent and selective gastrin/CCK-B receptor antagonist, on gastric acid secretion in beagle dogs with gastric fistula. Arzneim-Forsch Drug Res 1998, 48: 403-7.
115. Nishida, A., Takinami, Y., Yuki, H. et al. YM022, [(R)-1-]2,3-dihydro-1-(2′-methyl-phenacyl)-2-oxo-5-phenyl-1H-1,4- benzodiazepin-3-yl]-3-(3-ethylphenyl)urea), a potent and selective gastrin/cholecystokinin-B receptor antagonist, prevents gastric and duodenal lesions in rats. J Pharmacol Exp Ther 1994, 270: 1256-61.